Abstract
During the past few years, Epithelial-Mesenchymal Transition (EMT) has emerged as one of the most hot spots in clinical research. Its existence in human tumors can form the basis for explaining characteristics of cancer progression and metastasis, as well as certain cases of drug resistance and relapses after treatment. These cellular responses are tightly regulated by intracellular signaling pathways evoked by humoral factors that include growth factors, chemokines and cytokines. Indeed, several gene regulatory programs known to promote EMT during development have recently been discovered to play key roles in cancer progression. A deeper understanding of the cellular and molecular basis of these different programs should aid in both the development of better diagnosis methods, as well as of specific treatments for invasive cancer. In this review we set out to summarize recent novel insights into the molecular players underlying EMT and its relation with cancer progression and metastasis.
Keywords: Cancer, EMT, invasion, metastasis, MMP, NF-B, RTKs, TGF-, humoral factors, molecular players underlying EMT, epithelial cells phenotype, epithelial genes, cell-matrix interactions, pathological processes, cell surface E-cadherin
Current Pharmaceutical Biotechnology
Title: Epithelial-Mesenchymal Transition: Implications in Cancer Progression and Metastasis
Volume: 12 Issue: 11
Author(s): L. R. Gomes, L. F. Terra, M. C. Sogayar and L. Labriola
Affiliation:
Keywords: Cancer, EMT, invasion, metastasis, MMP, NF-B, RTKs, TGF-, humoral factors, molecular players underlying EMT, epithelial cells phenotype, epithelial genes, cell-matrix interactions, pathological processes, cell surface E-cadherin
Abstract: During the past few years, Epithelial-Mesenchymal Transition (EMT) has emerged as one of the most hot spots in clinical research. Its existence in human tumors can form the basis for explaining characteristics of cancer progression and metastasis, as well as certain cases of drug resistance and relapses after treatment. These cellular responses are tightly regulated by intracellular signaling pathways evoked by humoral factors that include growth factors, chemokines and cytokines. Indeed, several gene regulatory programs known to promote EMT during development have recently been discovered to play key roles in cancer progression. A deeper understanding of the cellular and molecular basis of these different programs should aid in both the development of better diagnosis methods, as well as of specific treatments for invasive cancer. In this review we set out to summarize recent novel insights into the molecular players underlying EMT and its relation with cancer progression and metastasis.
Export Options
About this article
Cite this article as:
R. Gomes L., F. Terra L., C. Sogayar M. and Labriola L., Epithelial-Mesenchymal Transition: Implications in Cancer Progression and Metastasis, Current Pharmaceutical Biotechnology 2011; 12 (11) . https://dx.doi.org/10.2174/138920111798377102
DOI https://dx.doi.org/10.2174/138920111798377102 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Modulation of Ischemic Brain Injury and Neuroinflammation by Adenosine A2A Receptors
Current Pharmaceutical Design Adrenomedullin and Nitric Oxide: Implications for the Etiology and Treatment of Primary Brain Tumors
CNS & Neurological Disorders - Drug Targets Cellular Targets for Anticancer Strategies
Current Drug Targets Therapeutic Strategies to Target Multiple Kinases in Glioblastoma
Anti-Cancer Agents in Medicinal Chemistry TGF-β2 Signaling in High-Grade Gliomas
Current Pharmaceutical Biotechnology Next Generation Antineoplastic Agents: A Review on Structurally Modified Vinblastine (VBL) Analogues
Current Medicinal Chemistry Anti-Epidermal Growth Factor Receptor Antibodies in the Treatment of Metastatic Colorectal Cancer
Recent Patents on Anti-Cancer Drug Discovery Matrix Metalloproteinase Inhibitor MMI-166 Suppresses the Growth of SW1990 Human Pancreatic Cancer Cells
Current Signal Transduction Therapy Telomerase Modulation in Therapeutic Approach
Current Pharmaceutical Design Modulation of Immuno-biome during Radio-sensitization of Tumors by Glycolytic Inhibitors
Current Medicinal Chemistry The GABAergic System and the Gastrointestinal Physiopathology
Current Pharmaceutical Design Herbal and Traditional Chinese Medicine for the Treatment of Cardiovascular Complications in Diabetes Mellitus
Current Diabetes Reviews The FKBP51-Glucocorticoid Receptor Balance in Stress-Related Mental Disorders
Current Molecular Pharmacology Neuroblastoma and Stem Cell Therapy: An Updated Review
CNS & Neurological Disorders - Drug Targets Eph/Ephrin Signalling and Function in Oncogenesis: Lessons from Embryonic Development
Current Cancer Drug Targets Spectrum of Radiopharmaceuticals in Nuclear Oncology
Current Cancer Drug Targets Structural Features of the Interleukin-10 Family of Cytokines
Current Pharmaceutical Design Therapeutic Potential of Metabotropic Glutamate Receptor Modulators
Current Neuropharmacology B7-H3-targeted Radioimmunotherapy of Human Cancer
Current Medicinal Chemistry The Antimitotic Potential of PARP Inhibitors, An Unexplored Therapeutic Alternative
Current Topics in Medicinal Chemistry